Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Jul
06
Today In Oncology
Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans
Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
AACR Statement and Call to Action Concerning OMB Proposal
Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo